Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 16, 2021 at 01:31 pm IST
Share
Zhejiang Garden Bio-chemical High-tech Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 158.982 million compared to CNY 135.433 million a year ago. Operating income was CNY 106.226 million compared to CNY 71.657 million a year ago. Net income was CNY 91.420 million compared to CNY 61.418 million a year ago. Basic earnings per share from continuing operations was CNY 0.17 compared to CNY 0.13 a year ago.
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. 
